Toshiyuki Oshitari Noriko Asaumi Masaru Watanabe Ken Kumagai Yoshinori Mitamura
10.2147/vhrm.s3446
Vasc Health Risk Manag
2008;4(5):1137-40.
diabetic macular edema optical coherence tomography pioglitazone spironolactone
NO-CC CODE
https://pubmed.ncbi.nlm.nih.gov/19183764/
Diabetes Mellitus, Type 2 / drug therapy Diabetic Retinopathy / etiology Hypoglycemic Agents / adverse effects Macular Edema / chemically induced Thiazolidinediones / adverse effects
Diabetes Mellitus, Type 2 / drug therapy Diabetic Retinopathy / etiology Hypoglycemic Agents / adverse effects Macular Edema / chemically induced Thiazolidinediones / adverse effects Case Reports Adult Diabetes Mellitus, Type 2 / complications Diabetes Mellitus, Type 2 / pathology Diabetic Retinopathy / pathology Diabetic Retinopathy / surgery Diuretics / therapeutic use Female Fluorescein Angiography Humans Light Coagulation Macular Edema / drug therapy Macular Edema / pathology Pioglitazone Severity of Illness Index Spironolactone / therapeutic use Tomography, Optical Coherence Treatment Outcome Visual Acuity / drug effects Diuretics Hypoglycemic Agents Thiazolidinediones Spironolactone Pioglitazone
PMC2605323
19183764
Severe macular edema induced by pioglitazone in a patient with diabetic retinopathy: a case study
2008